



TITLE Alternative uses for co-products: Harnessing the potential of valuable compounds from meat processing chains

AUTHORS Anne Maria Mullen, Carlos Álvarez, Dimitrios I. Zeugolis, Maeve Henchion, Eileen O'Neill, Liana Drummond

This article is provided by the author(s) and Teagasc T-Stór in accordance with publisher policies.

Please cite the published version.

The correct citation is available in the T-Stór record for this article.

NOTICE: This is the author's version of a work that was accepted for publication in *Meat Science*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Meat Science*, 2017, Available online 3 May 2017, <https://doi.org/10.1016/j.meatsci.2017.04.243>

This item is made available to you under the Creative Commons Attribution-Non commercial-No Derivatives 3.0 License.



1 **Alternative uses for co-products: Harnessing the potential of valuable compounds from**
2 **meat processing chains**

3
4 **Anne Maria Mullen^{1*}, Carlos Álvarez¹, Dimitrios I Zeugolis^{2,3}, Maeve Henchion⁴, E.**
5 **O'Neill⁵ & Liana Drummond¹**

6
7 1.- Teagasc Food Research Centre,. Dept of Food Quality and Sensory Science. Ashtown,
8 Dublin 15, Ireland

9 2.- Regenerative, Modular & Developmental Engineering Laboratory (REMODEL),
10 Biomedical Sciences Building, National University of Ireland Galway (NUI Galway),
11 Galway, Ireland

12 3. - Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM),
13 Biomedical Sciences Building, National University of Ireland Galway (NUI Galway),
14 Galway, Ireland.

15 4.- Teagasc Food Research Centre. Dept Agrifood Business and Spatial Analysis. Ashtown,
16 Dublin 15, Ireland.

17 5.- University College Cork, Department of Food & Nutritional Sciences, Cork, Dublin

18
19
20
21
22 *Corresponding author: Anne.mullen@teagasc.ie. Tel: + 00 35318059521

23 Teagasc Food Research Centre, Ashtown, Dublin 15, Ireland

24
25
26 **Abstract**

27 Opportunities for exploiting the inherent value of protein-rich meat processing co-products,
28 in the context of increased global demand for protein and for sustainable processing systems,
29 are discussed. While direct consumption maybe the most profitable route for some, this
30 approach is influenced greatly by local and cultural traditions. A more profitable and
31 sustainable approach may be found in recognizing this readily available and under-utilized
32 resource can provide high value components, such as proteins, with targeted high value
33 functionality of relevance to a variety of sectors. Applications in food & beverages, petfood

34 biomedical and nutrition arenas are discussed. Utilization of the raw material in its entirety is
35 a necessary underlying principle in this approach to help maintain minimum waste
36 generation. Understanding consumer attitudes to these products, in particular when used in
37 food or beverage systems, is critical in optimizing commercialization strategies.

38

39 **Highlights**

40 - Opportunities for extracting additional value from meat processing chain

41 - Meat co-products excellent source of proteins, vitamins, minerals and bio-actives

42 -High added-value uses can be developed to revalorize co-products

43

44

45 **Keywords**

46 Meat co-products, bioactive, protein, consumers, legislation, offal, valorisation, by-products

47

48 **1. Introduction**

49 Global pressures for increased supply of foods with high protein content, coupled with the
50 ever increasing demand for more efficient processing and increased financial rewards,
51 provides the imperative for the food industry to examine all processing streams with a view
52 to adding or recovering value. Based on its amino acid profile, animal protein can provide a
53 complete protein with a high biological value. In addition, meat, and in particular red meat,
54 provides a rich source of macro and micro-nutrients. Demand for this high quality product is
55 expected to continue to expand (FAO, 2009), which will lead to the increased production of
56 the lower value 'non meat' products such as offal, blood, etc., which have been estimated to
57 account for approximately 54-56% of the bovine and 48% of the porcine live animal weight
58 (Marti, Johnson, & Mathews Jr, 2012; Vernooij, 2012). In this review, such non-meat
59 products are referred to as co-products, similar to the view adopted in Australia.
60 Classification as animal by-products (ABPs) is not always relevant as this classification under
61 European legislation would restrict the use of these parts in the human food chain. While
62 many countries have secured markets for them, in general these tend to be low value markets,
63 often necessitating substantial transport costs. Even more, some of the products will carry a
64 neutral (no disposal cost) or negative (costs money to dispose of) value. Making better use of
65 the many co-products arising from meat processing, is not only important from a
66 sustainability perspective, but also offers opportunities to the industry to increase their value.

67 As discussed by many authors (Lynch, Mullen, O'Neill, & Álvarez, 2017; Mullen, Álvarez,
68 Pojić, Hadnadev, & Papageorgiou, 2015; Toldrá, Mora, & Reig, 2016) many of the materials
69 are rich sources of valuable components such as protein, lipids, biomolecules etc. While some
70 products command a reasonable value, and provide a nutritious food (Jayathilakan, Sultana,
71 Radhakrishna, & Bawa, 2012) when consumed directly, for others it may be more valuable to
72 extract separate components for discreet downstream applications. A five-stage universal
73 recovery process was suggested by Galanakis (2012) to describe this process of transforming
74 raw material into a final higher value product. While some of these steps can be eliminated or
75 merged this gives a good overview of the process. Both traditional and emerging technologies
76 of relevance are discussed in a later section. Optimal exploitation brings many challenges
77 such as product hygiene and stabilisation, economies of scale, product purity, consumer
78 attitudes and the requirement for efficient processing, which minimises the impact on the
79 environment. These challenges can be addressed both through good industry practice and an
80 applied research approach. Important principles to be guided by include that of total
81 exploitation, avoiding the generation of additional waste (Waldron, 2007), and the cascading
82 principle within the bioeconomy discourse which is about ensuring the highest value is
83 extracted first with lower value options only considered once the higher ones have been
84 exhausted.

85 Encouraging optimal utilisation of raw materials, early in the production chain, can help
86 ameliorate food waste losses before the product becomes more dispersed along the food
87 chain. The search for alternative protein sources has advanced in recent years (Van Huis et
88 al., 2013), and provides a relevant approach to meeting global protein requirements.
89 However, it is imperative to recognise that we have a readily available and under-utilised
90 resource ripe for exploitation in co-products arising from meat processing. As there is a link
91 between meat consumption and demand for protein-rich feed for livestock (Pimentel &
92 Pimentel, 2003; Trostle, 2008), it is imperative that all meat processing related proteins are
93 optimally exploited. This review covers applications relating to use in food and beverage
94 systems, petfood, nutrition focused and bioactive & biomedical applications. Market and
95 legislative information is provided in addition to an overview of relevant technologies and
96 consumer attitudes.

97

98 **2. Applications**

99 **2.1 Food ingredients**

100 Among other attributes proteins can impart techno-functional properties within a food or
101 beverage system. For example they may influence water holding capacity, viscosity, gelation,
102 emulsification and foaming. The ability of proteins to function in this manner is determined
103 by intrinsic e.g. amino acid profile, molecular structure and surface hydrophobicity, and by
104 extrinsic factors such as pH temperature, and ionic strength. Collagen, a fibrous, structural
105 protein, is one of the most abundant proteins. It is probably the animal protein most regularly
106 employed in food production. Following extraction and hydrolysis it can be transformed into
107 gelatine whose strong gelling properties are relevant to a variety of products such as soups,
108 gravies, desserts or dairy products (Hettiarachchy, Sato, Marshall, & Kannan, 2012).
109 Gelatine is mainly extracted from skin and bones. However, other offal such as lung, tongue,
110 trachea, large blood vessels, or tendons are, also, sources of collagen. Collagen has very
111 good film forming capacity which is exploited to generate casings and novel packaging
112 (Gómez-Guillén, Giménez, López-Caballero, & Montero, 2011). Other more specific
113 applications of collagen are described below in section 2.4, and have also been reviewed by
114 various authors (Ferraro, Anton, & Santé-Lhoutellier, 2016; Zeugolis, Paul, & Attenburrow,
115 2009). A variety of commercial collagen based products are available for use in food systems.
116 Examples of companies supplying them include Rousselot, Collapro and Devro, who provide
117 both clean label binders, gelling and textural agents or collagen based sausage casing.
118 Blood plasma comes second in line in meat co-product derived protein most employed as a
119 food ingredient. Following hygienic collection, centrifugation leads to the recovery of plasma
120 and cellular fractions (Lynch et al., 2017). Plasma can be used as it is, or dehydrated for
121 storage as a dry powder (Pares, Toldra, Saguer, & Carretero, 2014). Blood plasma is a
122 versatile product, which presents good emulsifying, gelling, foaming and solubility
123 properties. Applications of plasma in food industry see it used as a binder in meat products,
124 egg replacers in bakery, protein-rich pasta, fat replacers or even polyphosphate substitute
125 (Hsieh & Ofori, 2011; Hurtado et al., 2011). Some examples of plasma proteins currently in
126 the market are: Fibrimex® (purified fibrinogen used as binder), Immunolin® (concentrated
127 immunoglobulins, which improve the immune system)(Abu-Akkada & Awad, 2015), Myored
128 (natural red colorant), Vepro 95 HV (purified globin used as emulsifier) or Plasma Powder
129 FG (plasma with increased content of fibrinogen used as cold binder) (Ofori & Hsieh, 2012).
130 Apart from those two sources, the use of offal as sources of proteinaceous food ingredients
131 has not received a lot of research funding. In the last decade research has been published
132 describing the extraction and characterisation of functional proteins from various offal such
133 as: liver (Steen et al., 2016; Zou et al., 2017), lung (Selmane, Christophe, & Gholamreza,

134 2008), heart (Dewitt, Gomez, & James, 2002), viscera (Bhaskar, Modi, Govindaraju, Radha,
135 & Lalitha, 2007) or bones. (Linder, Fanni, Parmentier, Sergent, & Phan-Tan-Luu, 1995).
136 Very few patents, using offal as an ingredient, have been filed in the last 20 years; for
137 instance a patent filed in 2001 relates the use of offal as an ingredient for cheaper sausages or
138 burger patties (Van, 2001). But, in spite of the advances generated in food processing, most
139 of the patents found in the literature are from the 1960's and 1970's.

140 At a very basic, low value level, protein extracts from offal can be used as extender in
141 processed meat products (Heinz & Hautzinger, 2007). Recently, the use of pork tongue and
142 pork head meat as sausage ingredients has been reported, with no significant differences in
143 some quality characteristics compared to controls (Choi, Hwang, et al., 2016). Similar results
144 were observed when the final products were hamburger patties (Choi, Jeon, et al., 2016).
145 However, considering the functional properties of many of these proteins, there is a strong
146 argument to be made for capitalising on this high-value potential to more fully support a
147 sustainable use of natural resources. It is important to also remember that, as well as
148 providing proteins with nutritive value or good techno-functional characteristics, these co-
149 products are well established as being rich in minerals and vitamins (Mullen & Álvarez,
150 2016).

151

152 **2.2 Nutritional quality of co-products**

153 Nutritional quality of proteins has traditionally been defined based on the amino acid profile,
154 and the ability to provide specific patterns of amino acids for protein synthesis as measured
155 by animal growth or nitrogen balance in humans (Millward, Layman, Tomé, & Schaafsma,
156 2008). However, a more current definition describes this term as the ability of the protein to
157 achieve specific metabolic activities. Currently, the objective of protein quality evaluation is
158 determining the ability of a protein to reach maintenance needs, along with special needs as
159 growth, pregnancy or lactation (WHO, 2007). The up-to-date method approved for protein
160 quality determination is the protein digestibility-corrected amino acid score (PDCAAS). In
161 this method the single most limiting amino acid is identified, when compared to an
162 appropriate reference pattern, which defines the amino acid score. According to FAO,
163 Lysine, Methionine and Tryptophan are the most limiting amino acids in poor protein
164 sources. Table 1 shows the amount of these three amino acids, the total protein content and
165 the percentage of essential amino acids in a variety of offal from pork, beef and lamb. It can
166 be seen that offal, generally, is a good source of essential (namely Ile, Leu, Lys, Met, Phe,
167 Thr, Trp, Vali) and limiting amino acids. However, offal rich in connective tissue as ears,

168 feet, or lips, present a lowest protein quality, since connective tissue is mainly composed by
169 glycine, proline and alanine, which are not essential amino acids (Mullen & Álvarez, 2016).
170 This lack of essential amino acids can be overcome by tailor blending ingredients to achieve
171 a balanced amino acid profile in the final product.

172 Besides proteins, meat co-products can be a good source of minerals (Ca, Fe, Mg, Cu or Se)
173 or vitamins (niacin, Vit. B12, folate or Vit. C). Heme iron, mainly provided by meat and fish,
174 is more absorbable than non-heme iron (<15%); and also, although the mechanism is not well
175 defined, heme iron is more absorbed in the presence of meat, what is known as the “meat
176 factor” (López & Martos, 2004). Thus, it is worthy to explore if protein derived from offal
177 can also increase the bioavailability of iron, since they are a good iron source. Finally, the
178 offal fat content can vary from less than 1% in blood, up to 17% in tongue; with high
179 contents of saturated fatty acids. Among fats, it is important to draw attention to cholesterol
180 when referring to co-products, as some have high levels of this compound, as for example
181 kidneys, liver or brain (Mullen & Álvarez, 2016).

182 It is clear that meat co-products are rich sources of macro and micro-nutrients. Both these raw
183 materials and various extracts generated from them can be incorporated in products for
184 targeted end-users such as the elderly, sports-active or dairy intolerant consumers (Montero
185 Castillo, Ligardo, Alejandro, González, & Cristina, 2015).

186

187 **2.3 Bioactive compounds**

188 Bioactive compounds cover both peptides and other biomolecules which exert a
189 physiological benefit on consumption. Bioactive peptides or biopeptides are defined as short
190 sequences of 2 to 30 amino acids that exert this effect. These sequences are encrypted in the
191 parent protein and must be released from the parent protein to have an effect (Di Bernardini,
192 Harnedy, et al., 2011; Ryan, Ross, Bolton, Fitzgerald, & Stanton, 2011). In order to release
193 these encrypted amino acid sequences, three different techniques are employed: enzymatic
194 hydrolysis by means of commercial proteases (Sarmadi & Ismail, 2010); proteolytic
195 microorganism; or after fermentation or aging processes (Escudero et al., 2013). After any of
196 these processes, hundreds of peptides are generated, but only a few of them show biological
197 activity. For this reason, a further purification step must be carried out. Techniques such as
198 membrane filtration, chromatography or differential precipitation are commonly employed
199 (Power, Fernández, Norris, Riera, & FitzGerald, 2014). A different approach is to firstly
200 isolate the proteins, and then, carry out the hydrolysis step, which makes the further isolation
201 process easier. In order to optimise the screening process for bioactive peptide searching, *in*

202 *silico* tools can be employed (Fu et al., 2016): these are useful to find the right
203 protein/enzyme combination. As a complementary tool, the peptides of interest can be
204 synthesized at lab scale, in such way further studies of toxicology, functionality, absorption,
205 bioavailability or dose response can be performed (Korhonen & Pihlanto, 2006).

206 As discussed, the main component of meat co-products, on a dry basis, is protein; thus, these
207 by-products are a potential source of bioactive peptides which can be extracted, purified and
208 commercialised as a very high-added value product (Lemes et al., 2016). An ideal scenario is
209 one where proteins with key techno-functional characteristics are first extracted from the raw
210 material and the residual proteinaceous material subjected to biopeptide generation. An
211 example of this is seen on the ReValueProtein project (Álvarez, Lynch, Drummond, &
212 Mullen, 2016) where techno-functional proteins are extracted from lung and the non-
213 solubilised material used to generate bioactive peptides. Compared to other source materials
214 relatively few studies have looked at generating bioactive peptides from meat co-products.

215 Examples of bioactive peptides obtained from blood and meat are published or reviewed by
216 (Bah, Bekhit, Carne, & McConnell, 2013; Di Bernardini, Harnedy, et al., 2011; Toldra,
217 Aristoy, Mora, & Reig, 2012). However, a more limited number of studies can be found
218 using offal as a source (Di Bernardini, Rai, et al., 2011; Lee et al., 2010; O'Sullivan, Lafarga,
219 Hayes, & O'Brien, 2016). The types of activities reported have included antioxidant,
220 antimicrobial, antihypertensive, anti-diabetic, anti-hypercholesterolemic or mineral binding
221 (Sharma, Singh, & Rana, 2011). A number of important points need to be addressed to fully
222 capitalise on the value of these peptides. Ensuring that the peptides reach the target organ, are
223 non-toxic and both bioavailable and bioactive in the body is critical. The scale of processing
224 and the economic feasibility of same are also key considerations: which can be somewhat
225 mitigated by readily available, low price raw materials combined with novel hydrolysis and
226 purification steps (Agyei & Danquah, 2011).

227 Other molecules of interest, as health promoting compounds include creatine, carnosine,
228 carnitine, anserine and taurine. These naturally occurring low molecular weight molecules
229 can be found mainly in skeletal muscles and have many positive effects as: antioxidant,
230 lowering cholesterol, improved calcium absorption, preventing muscle myopathy, or
231 preventing heart disease (Williams, 2007) hence exudate and cook-out may be good sources.
232 It has also been reported that heart or liver can be a good source of these compounds
233 (Hoffmann, Waszkiewicz-Robak, & Świdorski, 2010). Though not the subject of this review,
234 many other active compounds can be found in meat and may also be present in co-products,
235 such as: conjugated linoleic acid (CLA), chondroitin sulphate, Coenzyme Q10, spermidine,

236 choline, lipoic acid, or glutathione (Arihara & Ohata, 2008). The main biological activities
237 are summarized in Table 2.

238

239 **2.4 Biomedical applications**

240 Natural biomaterials such as collagen present many opportunities outside of food sector and
241 in particular can serve as raw materials in biomedical applications. The term ‘collagen’
242 encompasses a family of glycoproteins that are characterised by a repeating [Glycine-X-Y]_n
243 amino acid sequence (X is usually proline and Y is frequently hydroxyproline). To-date,
244 twenty-nine genetically distinct collagen types have been described that can be classified in
245 four broad categories [fibrous (e.g. types I, II, III), non-fibrous (e.g. types IV, VII, XXVIII),
246 filamentous (e.g. types VI, VIII, X) and fibril associated with interrupted triple helices (e.g.
247 types IX, XII, XIV) collagens], based on their primary structure, molecular weight, charge
248 profile along the helix, length of the triple helix, size and shape of the terminal globular
249 domains. In vertebrates, collagen is the major constituent of connective tissues, comprising
250 almost 25 % of total body proteins, 75 % of the dry weight of skin, 80 % of the organic
251 matter in bones and 90 % of tendon and corneal tissues. The abundance of this extracellular
252 matrix protein, in addition to its inherent bioactivity, molecular recognition signals,
253 controllable mechanical and degradation properties and its ability to be reconstructed in
254 various three-dimensional architectures (e.g. fibres, sponges, films, spheres, hydrogels), make
255 it an ideal raw material for biomaterials, tissue engineering and drug / gene / cell delivery
256 applications (Abbah et al., 2015; Kielty & Grant, 2002; Soroushanova et al., Submitted;
257 Thomas et al., 2016).

258 In biomedicine, porcine and bovine skin and tendon tissues are the main source of collagen
259 type I, whilst collagen type II is extracted from porcine and bovine articular cartilage. Fish
260 industry by-products (e.g. skin, scales and bones) have also been used to extract collagen for
261 the fabrication of biomaterials, but to a smaller extent. Independently of the source (e.g.
262 mammalian or fish), purified collagens are extracted using primarily dilute acids with or
263 without enzymes. Dilute acids disassociate mild intermolecular aldimine cross-links, whilst
264 proteolytic enzymes (e.g. pepsin) are effective even against stable ketoimine bonds, not only
265 increasing the yield for up to 10 times, but also lowering immune response in patients,
266 through the removal of the antigenic sequence P-determinant, located at the telo-peptide
267 regions (Bruckner & Prockop, 1981; Lynn, Yannas, & Bonfield, 2004; D. I. Zeugolis, Paul,
268 & Attenburrow, 2008). While collagen and collagen-like molecules can be produced using
269 various cell types, recombinant systems and peptide synthesis; these technologies are still

270 very expensive, of low yield, and produce unstable collagens. Compared to animal extracted
271 collagen they have increased susceptibility to proteolytic degradation, restricting their use in
272 biomedicine (Browne, Zeugolis, & Pandit, 2013; Fichard, Tillet, Delacoux, Garrone, &
273 Ruggiero, 1997; Frischholz et al., 1998; Myllyharju et al., 1997; Vuorela, Myllyharju, Nissi,
274 Pihlajaniemi, & Kivirikko, 1997). All these factors support continued expansion of the use of
275 collagen in the biomedicine, food and cosmetic industry.

276

277 **2.5 Pet food and animal feed**

278 As nutritious sources of protein, fat and micronutrients many products are highly suitable for
279 use in companion animal diets (Cramer et al., 2007; Rivera, 1998). As rich sources of protein
280 and as a result of regular use in pet food formulations they have been considered a major
281 contributor to the growth of the pet food industry (Corbin, 1992). In canine diets they provide
282 good sources of digestible nutrients in particular proteins and fat (Murray et al 1997).
283 Palatability is an important consideration in pet foods formulation. Co-products can also
284 serve as palatability enhancers (Boskot, 2009) which will have a direct impact on product
285 acceptability. The pet food market has seen strong growth with pet humanisation and
286 premiumisation being considered key drivers. As well as being incorporated into petfoods
287 these products are also sold in pet stores as treat type products e.g. bone, hides, ears etc.
288 Animal feeds play an important role in the global food industry as they influence greatly the
289 ability to produce animals in an economical way. In particular, following rendering, co-
290 products arising from meat processing form an important constituent in animal feeds
291 (Jayathilakan, Sultana, Radhakrishna, & Bawa, 2012).

292

293 **3. Market overview**

294 The categorization and utilization of a secondary stream as a co-product is dependent on
295 several factors such as local and export market demands, existing profitable applications and
296 a favourable and feasible commercialization route. Broadly speaking, depending on local
297 cultural habits, the market for 5th quarter products such as offal and blood is shared between
298 exports, pet food, animal feed and local direct consumption.

299 Clear opportunities for exploring a variety of meat co-products have been identified over the
300 years in scientific research studies and market trend reports. However, an effective market
301 analysis of this area needs to take account not only of the latest R&D and scientific advances
302 in the recovery and reutilization of compounds from co-product materials, but also of
303 industry activities currently in place, as well as existing market and commercial scenario of

304 the original products, since re-direction of a stream may have impacts on established supply
305 chains and ancillary commercialization routes. Several markets with existing or future
306 potential based on co-products are briefly presented below.

307 The protein market is generally divided by applications: food and beverage, sports nutrition,
308 animal feed, cosmetics and personal care, pharmaceuticals, etc. For the sports nutrition
309 category in particular, protein stands as the main driving force (Schmidt, 2014). In Ireland
310 and other markets, protein powders are still the most popular type of sports nutrition product,
311 but other more convenient formats such as protein ready-to-drink products and protein bars
312 are quickly becoming more popular (Hickey, 2014). As reported by Glanbia “the global
313 performance nutrition market, at retail selling price, is approximately \$10.1 billion with the
314 USA accounting for 63%, and other international markets accounting for 37%”
315 (Glanbia.com, 2017). Although whey proteins still dominate this market, due to
316 diversification of products and applications, blends incorporating other sources of proteins
317 are increasingly gaining ground.

318 The market size for functional foods may be difficult to measure, as the exact definition of a
319 functional food can vary between regions, countries or even companies. Nonetheless, some
320 analysts value it at up to USD 190 Bn worldwide, showing a growing of 6–25% per year, and
321 with the same perspective for the next 5 years (Calvo, Martorell, Genovés, & Gosálbez,
322 2016).

323 The global collagen market is forecast to expand at a 9.4 % compound annual growth rate
324 from 2015 to 2023 and the market is projected to rise to US\$ 9.37 billion by 2023 ("Collagen
325 market - Global industry analysis, size, share, growth, trends, and forecast 2015 – 2023,"
326 Transparent Market Research Report 2016). Currently, around 60% is due to gelatine
327 production (Global Market Insights report, 2015). Other markets which go beyond food and
328 beverage include the use of collagen for biomedical applications and the manufacture of
329 advanced biomaterials, for tissue regeneration for example, an area reported to be expanding
330 rapidly (Global Market Insights report, 2015). Collagen has also attracted much interest as a
331 source of functional peptides, with applications in the health, cosmetics and personal care
332 areas.

333 The challenges in obtaining approval for peptides as ingredients with beneficial health
334 properties has undoubtedly influenced the growth of this market, but for products which
335 receive approval there are clear rewards. In 2012 while approved peptide drugs were
336 estimated to command only about 2% of the global drug market the value represented
337 approximately USD 20 billion (Sun, 2013).

338 Key markets for animal blood include the food industry, animal feed and pet food
339 applications. It is estimated that the food industry utilizes about 30% of blood produced from
340 slaughter in different forms, for example plasma used as an emulsifier or whole blood used in
341 traditional products (Bah et al., 2013). The value of the US dried animal blood plasma market
342 for animal feed in 2010 was estimated in USD 29 million per annum (Wilson, 2011). The
343 possibility of obtaining bioactive peptides from blood could lead to higher value products
344 being produced, giving access to the expanding functional and nutraceutical applications
345 market. Further efforts for the extraction and valorisation of protein from animal blood may
346 also increase the use of blood as a source of techno-functional compounds for food and
347 beverage applications.

348 While the export market for some 5th quarter products offer the greatest opportunity to
349 increase margins from edible offal, consumer perceptions in relation to food scares or disease
350 outbreaks may have an unjustifiable impact of product values. Additionally, an understanding
351 of specific market requirements is necessary, to satisfy demands in terms of customs and
352 expectations.

353

354 **4. Consumer studies**

355 Humans seek novelty and variety in their diet for nutrition and health reasons and to satisfy
356 pleasure seeking motives (Al-Shawaf, Lewis, Alley & Buss, 2015). However they are also
357 wary of foods with which they are unfamiliar, due to fears in relation to food safety and
358 health. This led to the phrase “the omnivores dilemma” to reflect individual’s competing
359 motives of neophobia and neophilia (Martins, Pelchat & Pliner, 1997). Reflecting differences
360 in cultures, meat co-products are regarded as delicacies in some countries, however most
361 consumers in developed countries are unfamiliar with meat co-products, such that many have
362 never tasted offal and most have a very limited knowledge about how to prepare and cook it.
363 Some may even regard them as unhealthy or waste (Frewer & Gremmen, 2007).

364 Three important factors may lead to the rejection of unfamiliar food products: negative
365 sensory properties, harmful consequences and “ideational” factors (Rozin & Fallon, 1987).
366 Henchion et al (2016) found such factors at play in consumer evaluations of a range of
367 product concepts that incorporated ingredients derived from offal. On the negative side,
368 consumers were concerned with the taste and texture of such products, did not see significant
369 benefits, were disgusted with the idea that the ingredients originated in live animals and even
370 questioned if such products were edible. However this research also found that processing
371 could have a positive influence on acceptance through its influence on the physical form of

372 the ingredient. Changing the physical form of the ingredient resulted in “de-animalising” the
373 ingredient and for some consumers shifted the focus away from emotive, ideational factors,
374 and allowing them to consider the product’s characteristics and benefits. The impact of
375 processing is however complex with increased processing resulting in negative perceptions
376 regarding healthiness and naturalness in some contexts.

377 Integrating unfamiliar foods into existing culinary and dietary practices was identified as
378 supporting acceptance in the context of insect-based foods (Looy, Dunkel, & Wood, 2014).
379 Research by Henschion et al (2016) reports similar findings with regards to meat co-products
380 suggesting that this strategy could also work for meat co-products. They argue that meat co-
381 products should be presented to consumers as ingredients rather than finished products to
382 give them flexibility in terms of how they are integrated into consumers’ routines.

383 The role of experts, celebrity chefs and friends in providing evidence that consumption of
384 unfamiliar products is safe and socially acceptable is highlighted in relation to meat co-
385 products in some niche markets. Boutique butchers with traditional “fancy meats” and
386 restaurants featuring nose-to-tail eating are becoming more prevalent in the UK for example,
387 resulting in changes in the consumer landscape, with a claim by Datamonitor (2014) that
388 “offal is officially in”, due to experimentation, consciousness of value and increased
389 availability.

390

391 **5. Legislation**

392 To explore and commercialise the range of available co-products of animal origin it is
393 necessary to understand relevant legislation, rules and regulations governing access to source
394 materials and markets. Information and guidance on how material is to be collected, handled,
395 stored, processed, etc. will determine not only the value of the final product, but crucially
396 ensure compliance for downstream uses. It can be said that legislation was developed for two
397 distinct groups: unusable and usable by-products (Leoci, 2014). For unusable by-products,
398 associated regulations lay down handling and disposal rules to safeguard the environment and
399 public health. On the other hand, for by-products posing no risk to health or the environment,
400 and for which a viable commercial application exists, regulations may relate to materials’
401 collection, transport and further processing.

402 In the European Union, the term animal by-product (ABP), is reserved for products of animal
403 origin that are not intended for human consumption and use or disposal of ABP is strictly
404 controlled. Depending on the risk they pose, ABPs are divided into categories 1, 2 and 3,
405 category 1 being the highest in risk. The classification of some 5th quarter products as edible

406 or inedible can be influenced by collection and handling conditions and on local or existing
407 export markets. If intended for human consumption, 5th quarter products are covered under
408 regulations for food of animal origin, and should not be classified as ABPs.

409 Since the bovine spongiform encephalopathy (BSE) crises, rules for the prevention, control
410 and eradication of certain transmissible spongiform encephalopathies (TSEs) set out in
411 Regulation 999/2001, have irreversibly excluded parts of the carcass from the food chain.
412 The regulation covers the production, placing on the market and, in some cases, the export of
413 animals and animal products. For feed and pet food, for example, only category 3 material is
414 allowed. Directive 2008/98/EC on waste includes a definition and the main conditions which
415 must be met by a substance to be classified as a by-product. The regulation encourages the
416 reuse, reutilization and recycling of non-hazardous by-products. Also relevant, Directive
417 2008/1/EC prohibits discharging of blood into digesters and sets down an obligation of using
418 blood for other purposes.

419 Regulation (EC) No 1069/2009 includes health rules as regards animal by-products and
420 derived products not intended for human consumption (uses other than for food). However,
421 some products are not covered by this Regulation. These include cosmetic products
422 (Directive 76/768/EEC); medical implants (Directive 90/385/EEC); medical devices
423 (Directive 2003/32/EC); In vitro diagnostic medical devices (Directive 89/79/EC); veterinary
424 medical products (Directive 2001/82/EC); and medicinal products (Directive 2001/83/EC).

425 For parts of the carcass intended for human consumption, the "Hygiene Package": Regulation
426 (EC) 852/2004, Regulation (EC) 853/2004 and Regulation (EC) 854/2004), must apply, as
427 well as the Regulation (EC) 1169/2011 for the provision of food information to consumers.

428 From the perspective of food hygiene regulations, offal is defined as: "fresh meat other than
429 that of the carcass, including viscera and blood" (EC) 854/2004). However, from an
430 ingredient labelling perspective, Regulation (EC) 1169/2011 restricts the definition of "meat"
431 to skeletal attached muscles. Any other parts of the animal must be declared separately and
432 the meat species must be identified on the label (e.g.: "beef heart protein" or "bovine heart
433 protein"), which can have an impact on consumer perception of these food ingredients.

434 Also relevant, assuming they are utilised in products for these target audiences, Regulation
435 (EU) No 609/2013 on food intended for infants and young children, food for special medical
436 purposes, and total diet replacement for weight control, lays down general rules on the
437 composition and preparation of foods that are specially designed to meet the particular
438 nutritional requirements of the persons for whom they are intended.

439 Regulation 1333/2008 (latest consolidated version published February 2016) covers food
440 additives and lists substances that are not considered as additives, and hence not covered by
441 this regulation, which includes blood plasma, protein hydrolysates and their salts. These are
442 also not considered meat and must be declared separately on the label. Annex II to Regulation
443 1333/2008, amended by Regulation (EU) 601/2014, lays down a list of approved food
444 additives and their conditions of use. Food additives are listed on the basis of the categories
445 of food to which they may be added to, with Category 8 covering processed and unprocessed
446 meat. Food enzymes are covered separately by Regulation (EC) 1332/2008.

447 In the United States, Title 9 of the Code of Federal Regulations (CFR) provides the rules
448 governing animals, and animal products. It includes two groups of protein contributing
449 ingredients: Group 1 includes ingredients of livestock or poultry origin from muscle tissue
450 which are skeletal or found in the edible organs, with or without the accompanying and
451 overlying fat, and the portions of bone, skin, sinew, nerve, and blood vessels which normally
452 accompany the muscle tissue, not separated in the process of dressing, as well as meat by
453 products; mechanically separated (species); and poultry products. Ingredients processed by
454 hydrolysis, extraction, concentrating or drying are part of Group 2 Protein-Contributing
455 Ingredients along with any other ingredient which contributes protein. An up-to-date list of
456 substances considered as safe and suitable ingredients for the production of meat, poultry and
457 egg products is published in a regularly revised directive from the USDA-FSIS, currently
458 Revision 39, from January, 2017. The list includes beef protein as a food grade substance
459 approved as generally recognized as safe (GRAS), for use in meat, poultry and egg products.
460 Federal regulation (USDA-FSIS, 1999) lays down the rules and regulations for collection and
461 processing of blood when intended for human consumption.

462 Meat protein ingredients are considered non-allergenic and are generally “minimally
463 processed”. Additionally, their nomenclature is more easily recognised. Although this can
464 make them more consumer-friendly, it may also negatively affect consumer perception. Table
465 3 summarizes the current legislative scenario in Europe, regarding the use of meat co-
466 products.

467 **6. Relevant technologies**

468 Traditional methods such as chemical precipitation, ultrafiltration, extrusion, lyophilisation,
469 isoelectric solubilization-precipitation or solvent extraction are widely employed in order to
470 extract and concentrate proteins and peptides from waste materials (Galanakis, 2015).
471 Depending on the raw material, and the final application of the extract, one of these methods,
472 or a combination of them, has to be selected. However, some of the methods above

473 mentioned, may have a negative impact on the activity of the desired compounds, since heat
474 treatment (for instance evaporation, pasteurization or extrusion) or denaturing chemicals
475 (ethanol, strong acids or alkalis) might irreversibly affect the structure and chemical
476 properties of the target compounds. In the particular case of proteins and peptides, negative
477 processing effects are (Korhonen, Pihlanto-Leppäla, Rantamäki, & Tupasela, 1998):

- 478 i) Heat treatment: destruction of heat sensitive peptides, cross linkages, protein
479 denaturation
- 480 ii) pH: racemization, destruction of amino acids, risk of oxidation
- 481 iii) Membrane filtration: change in amino acid composition
- 482 iv) Storage: destruction of lysine and oxidation.

483 These changes can lead to a loss of protein functionality, nutritive value or bioactivity;
484 reducing the final value of the product and narrowing their field of application. In order to
485 minimise or prevent such modifications, novel technologies are being developed. Such
486 technologies usually overcome the negative impacts of thermal treatments and additionally,
487 minimise significantly the amount, and hence the effect, of solvents and reagents employed
488 for protein/peptide extraction.

489 Most promising and emerging technologies for protein extraction are those based on
490 ultrasounds (Kadam, Tiwari, Álvarez, & O'Donnell, 2015); pulsed electric fields (PEF)
491 (Soliva-Fortuny, Balasa, Knorr, & Martín-Belloso, 2009); high hydrostatic pressures (HHP)
492 (Li, Zhu, Zhou, & Peng, 2012); sub-critical water hydrolysis (SWH) (Marcet, Alvarez,
493 Paredes, & Diaz, 2016); or laser ablation (Boutinguiza et al., 2007). Among these
494 techniques, ultrasounds and PEF have been reported to produce negligible changes in protein
495 composition and structure (Chandrapala, Zisu, Palmer, Kentish, & Ashokkumar, 2011;
496 Garde-Cerdán, Arias-Gil, Marsellés-Fontanet, Ancín-Azpilicueta, & Martín-Belloso, 2007).
497 On the other hand, HHP and SWH, can produce drastic changes in protein structure as non-
498 reversible unfolding or hydrolysis (Smeller, 2002). Other technologies which hold potential
499 for these products include aqueous two phase extraction, foam mat drying, and others
500 reported by Galanakis (2012). Table 4 presents how, through the application of currently
501 available technologies, is possible to obtain high added-value products from the various co-
502 products generated by the meat industry.

503 There is little evidence of the application of many of these emerging technologies for
504 extracting value from meat co-products. More effort has been seen in optimizing the use of
505 these emerging technologies on vegetables, seaweeds and dairy products. There clearly is a
506 pressing need to examine the relevance of transferring these developments into the meat

507 sector in terms for example of both recovery yields and impact on functionality of final
508 product.

509

510 **7. Conclusions**

511 Opportunities clearly exist for extracting additional value from meat processing chains. As
512 well as ensuring optimal use of such a protein rich material this approach also supports
513 sustainable practices across the sector sector and will be increasingly necessary in a world of
514 growing demand and constrained resources. Science and technology driven approaches must
515 be coupled with market, legislative and consumer knowledge for successful
516 commercialisation of the downstream products.

517

518 **Acknowledgements:**

519 This work forms part of the ReValueProtein Research Project (Grant Award No. 11/F/043)
520 which is supported by the Irish Department of Agriculture, Food and the Marine (DAFM)
521 and the Food Institutional Research Measure (FIRM) both funded by the Irish Government
522 under the National Development Plan 2007-2013.

523

524 **8. Bibliography**

- 525 Abbah, S., Delgado, L., Azeem, A., Fuller, K., Shologu, N., Keeney, M., . . . Zeugolis, D. (2015).
526 Harnessing hierarchical nano- and micro-fabrication technologies for musculoskeletal tissue
527 engineering. *Adv Healthc Mater*, 4(16), 2488-2499.
- 528 Abu-Akkada, S. S., & Awad, A. M. (2015). Protective effects of probiotics and prebiotics on Eimeria
529 tenella-infected broiler chickens. *Pak. Vet. J*, 35, 446-450.
- 530 Agyei, D., & Danquah, M. K. (2011). Industrial-scale manufacturing of pharmaceutical-grade
531 bioactive peptides. *Biotechnology Advances*, 29(3), 272-277.
- 532 Al-Shawaf, L., Lewis, D. M. G., Alley, T. R. & Buss, D. M. (2015). Mating strategy, disgust, and food
533 neophobia, *Appetite*, 85, 30-35.
- 534 Álvarez, C., Lynch, S., Drummond, L., & Mullen, A. M. (2016). A multidisciplinary approach for the
535 recovery and revalorisation of proteins from bovine and porcine co-products. [Oral
536 communication]. *Congreso Iberoamericano de Biotecnología*, 1(1), 195.
- 537 Arihara, K., & Ohata, M. (2008). Bioactive compounds in meat *Meat biotechnology* (pp. 231-249):
538 Springer.
- 539 Bah, C. S. F., Bekhit, A. E.-D. A., Carne, A., & McConnell, M. A. (2013). Slaughterhouse Blood: An
540 Emerging Source of Bioactive Compounds. *Comprehensive Reviews in Food Science and Food*
541 *Safety*, 12(3), 314-331.
- 542 Bhaskar, N., Modi, V., Govindaraju, K., Radha, C., & Lalitha, R. G. (2007). Utilization of meat industry
543 by products: protein hydrolysate from sheep visceral mass. *Bioresource technology*, 98(2),
544 388-394.
- 545 Boskot, S. (2009) Production of pet food: inclusion of palatability enhancers in dry extruded dog
546 food. Lambert Academic Publishing AG & Co KG, Germany.

547 Boutinguiza, M., Lusquiños, F., Comesaña, R., Riveiro, A., Quintero, F., & Pou, J. (2007). Production of
548 microscale particles from fish bone by gas flow assisted laser ablation. *Applied Surface*
549 *Science*, 254(4), 1264-1267.

550 Browne, S., Zeugolis, D. I., & Pandit, A. (2013). Collagen: Finding a solution for the source. *Tissue Eng*
551 *A*, 19(13-14), 1491-1494.

552 Bruckner, P., & Prockop, D. J. (1981). Proteolytic-enzymes as probes for the triple-helical
553 conformation of procollagen. *Anal Biochem*, 110(2), 360-368.

554 Calvo, D. R., Martorell, P., Genovés, S., & Gosálbez, L. (2016). Development of novel functional
555 ingredients: Need for testing systems and solutions with *Caenorhabditis elegans*. *Trends in*
556 *Food Science & Technology*, 54, 197-203.

557 Chandrapala, J., Zisu, B., Palmer, M., Kentish, S., & Ashokkumar, M. (2011). Effects of ultrasound on
558 the thermal and structural characteristics of proteins in reconstituted whey protein
559 concentrate. *Ultrasonics Sonochemistry*, 18(5), 951-957.

560 Choi, Y.-S., Hwang, K.-E., Kim, H.-W., Song, D.-H., Jeon, K.-H., Park, J.-D., . . . Kim, C.-J. (2016).
561 Replacement of Pork Meat with Pork Head Meat for Frankfurters. *Korean Journal for Food*
562 *Science of Animal Resources*, 36(4), 445.

563 Choi, Y.-S., Jeon, K.-H., Ku, S.-K., Sung, J.-M., Choi, H.-W., Seo, D.-H., . . . Kim, Y.-B. (2016). Quality
564 characteristics of replacing pork hind leg with pork head meat for hamburger patties. *Korean*
565 *journal of food and cookery science*, 32(1), 58-64.

566 Collagen market - Global industry analysis, size, share, growth, trends, and forecast 2015 – 2023.
567 (2016): Transparency Market Research.

568 Corbin, J.E. (1992) Inedible meat, poultry and fish by-products in pet foods. In Pearson, A.M. and
569 Dutson, T.R. (eds) Inedible meat by-products. *Advances in meat research*, Vol 8. Pp 329-347,
570 Elsevier Applied Science, London.

571 Cramer, K. R., Greenwood, M. W., Moritz, J. S., Beyer, R. S. & Parsons, C. M. (2007) Protein quality of
572 various raw and rendered by-product meals commonly incorporated into companion animal
573 diets. *Journal of Animal Science*. 85:3285–3293.

574 Datamonitor. (2014) Consumer and Innovation trends in Meat Fish and Poultry 2014. Available at:
575 http://www.datamonitor.com/store/Product/consumer_and_innovation_trends_in_meat_fi
576 [sh_and_poultry_2014?productid=CM00198-064](http://www.datamonitor.com/store/Product/consumer_and_innovation_trends_in_meat_fi). Accessed February 2017

577 Dewitt, C., Gomez, G., & James, J. (2002). Protein extraction from beef heart using acid
578 solubilization. *Journal of food science*, 67(9), 3335-3341.

579 Di Bernardini, R., Harnedy, P., Bolton, D., Kerry, J., O'Neill, E., Mullen, A. M., & Hayes, M. (2011).
580 Antioxidant and antimicrobial peptidic hydrolysates from muscle protein sources and by-
581 products. *Food Chemistry*, 124(4), 1296-1307.

582 Di Bernardini, R., Rai, D. K., Bolton, D., Kerry, J., O'Neill, E., Mullen, A. M., . . . Hayes, M. (2011).
583 Isolation, purification and characterization of antioxidant peptidic fractions from a bovine
584 liver sarcoplasmic protein thermolysin hydrolyzate. *Peptides*, 32(2), 388-400.

585 Escudero, E., Mora, L., Fraser, P. D., Aristoy, M.-C., Arihara, K., & Toldrá, F. (2013). Purification and
586 identification of antihypertensive peptides in Spanish dry-cured ham. *Journal of proteomics*,
587 *78*, 499-507.

588 EC Regulation 999/2001. Rules for the prevention, control and eradication of certain
589 transmissible spongiform encephalopathies. *Official Journal of the European Union*, 147, 1–69

590 EC Regulation 853/2004. Specific hygiene rules for on the hygiene of foodstuffs. *Official Journal of*
591 *the European Union*, 139, 1–55.

592 EC Directive 2008/98/EC on waste and repealing certain Directives. *Official Journal of the European*
593 *Union*, 312, 3-30

594 EC Directive 2008/1/EC concerning integrated pollution prevention and control. *Official Journal of*
595 *the European Union*, 24, 8-29

596 EC Regulation 1333/2008. Food additives. *Official Journal of the European Union*, 354, 16- 33

597 EC Regulation 1069/2009. Health rules as regards animal by-products and derived products not
598 intended for human consumption. Official Journal of the European Union, 300, 1–33
599 EC Regulation 1169/2011. Provision of food information to consumers. Official Journal of the
600 European Union, 304, 18-62
601 EC Regulation 609/2013. Food intended for infants and young children, food for special medical
602 purposes, and total diet replacement for weight control. Official Journal of the European
603 Union, 181, 35-56.
604 Fallas, J. A., O'Leary, L. E., & Hartgerink, J. D. (2010). Synthetic collagen mimics: Self-assembly of
605 homotrimers, heterotrimers and higher order structures. *Chem Soc Rev*, 39(9), 3510-3527.
606 FAO. How to Feed the World in 2050. (2009). Available from: http://www.fao.org/fileadmin/templates/wsfs/docs/expert_paper/How_to_Feed_the_World_in_2050.pdf. Accessed on February 2017.
607
608 Ferraro, V., Anton, M., & Santé-Lhoutellier, V. (2016). The “sisters” α -helices of collagen, elastin and
609 keratin recovered from animal by-products: Functionality, bioactivity and trends of
610 application. *Trends in Food Science & Technology*, 51, 65-75.
611
612 Frewer, L.J. & Gremmen, B. (2007). Consumer's interests in food processing waste management and
613 co-product recovery. In: Waldron K (Ed) Handbook of waste management and co-product
614 recovery in food processing, vol. 1. Cambridge, UK: Woodhead Publishing, 21-33.
615 Fichard, A., Tillet, E., Delacoux, F., Garrone, R., & Ruggiero, F. (1997). Human recombinant alpha1(V)
616 collagen chain. Homotrimeric assembly and subsequent processing. *J Biol Chem*, 272(48),
617 30083-30087.
618 Frischholz, S., Beier, F., Girkontaite, I., Wagner, K., Pöschl, E., Turnay, J., . . . von der Mark, K. (1998).
619 Characterization of human type X procollagen and its NC-1 domain expressed as
620 recombinant proteins in HEK293 cells. *J Biol Chem*, 273(8), 4547-4555.
621 Fu, Y., Young, J. F., Løkke, M. M., Lametsch, R., Aluko, R. E., & Therkildsen, M. (2016). Revalorisation
622 of bovine collagen as a potential precursor of angiotensin I-converting enzyme (ACE)
623 inhibitory peptides based on in silico and in vitro protein digestions. *Journal of Functional
624 Foods*, 24, 196-206.
625 Galanakis, C. M. (2012). Recovery of high added-value components from food wastes: Conventional,
626 emerging technologies and commercialized applications. *Trends in Food Science &
627 Technology*, 26(2), 68-87.
628 Galanakis, C. M. (2015). Chapter 3 - The universal recovery strategy *Food Waste Recovery* (pp. 59-
629 81). San Diego: Academic Press.
630 Garde-Cerdán, T., Arias-Gil, M., Marsellés-Fontanet, A. R., Ancín-Azpilicueta, C., & Martín-Belloso, O.
631 (2007). Effects of thermal and non-thermal processing treatments on fatty acids and free
632 amino acids of grape juice. *Food Control*, 18(5), 473-479.
633 Gauba, V., & Hartgerink, J. D. (2008). Synthetic collagen heterotrimers: Structural mimics of wild-
634 type and mutant collagen type I. *J Am Chem Soc*, 130(23), 7509-7515.
635 Glanbia.com. (2017). *Markets & Locations*. [online] Available at: <https://www.glanbia.com/our-business/global-performance-nutrition/markets-and-locations> [Accessed 5 Apr. 2017].
636
637 Global Market Insights report (2015). Collagen Market Size, Industry Analysis Report, Regional
638 Outlook (U.S., Germany, UK, Italy, Russia, China, India, Japan, South Korea, Brazil, Mexico,
639 Saudi Arabia, UAE, South Africa), Application Development Potential, Price Trend,
640 Competitive Market Share & Forecast, 2016 – 2023. Available on
641 <https://www.gminsights.com/industry-analysis/collagen-market> Accessed on February 2017.
642 Gómez-Guillén, M., Giménez, B., López-Caballero, M. a., & Montero, M. (2011). Functional and
643 bioactive properties of collagen and gelatin from alternative sources: A review. *Food
644 Hydrocolloids*, 25(8), 1813-1827.
645 Heinz, G., & Hautzinger, P. (2007). *Meat processing technology for small to medium scale producers:*
646 FAO.

647 Henchion, M, McCarthy, M & J. O'Callaghan (2016), Transforming beef by-products into valuable
648 ingredients: which spell/recipe to use? *Front. Nutr. - Nutrition and Food Science Technology*,
649 In press

650 Hettiarachchy, N. S., Sato, K., Marshall, M. R., & Kannan, A. (2012). *Food proteins and peptides:*
651 *chemistry, functionality, interactions, and commercialization*: CRC Press.

652 Hickey, G. (2014) Bord Bia Food Alert: Sports Nutrition now more convenient than ever in Ireland.
653 Available on: <http://www.bordbia.ie/industry/manufacturers/insight/alerts/Pages/SportsNutritionnowmoreconvenientthaneverinIreland.aspx?year=2014&wk=24>. Accessed on
654 February 2017.

655

656 Hoffmann, M., Waszkiewicz-Robak, B., & Świdorski, F. (2010). Functional food of animal origin. Meat
657 and meat products. *Nauka Przyroda Technologie*, 4(5), # 63.

658 Hsieh, Y.-H. P., & Ofori, J. A. (2011). Blood-derived products for human consumption. *Revelation and*
659 *Science*, 1(01).

660 Hurtado, S., Dagà, I., Espigulé, E., Parés, D., Saguier, E., Toldrà, M., & Carretero, C. (2011). Use of
661 porcine blood plasma in "phosphate-free frankfurters". *Procedia Food Science*, 1, 477-482.

662 Jayathilakan, K., Sultana, K., Radhakrishna, K., & Bawa, A. S. (2012). Utilization of byproducts and
663 waste materials from meat, poultry and fish processing industries: a review. *J Food Sci*
664 *Technol*, 49(3), 278-293.

665 Kadam, S. U., Tiwari, B. K., Álvarez, C., & O'Donnell, C. P. (2015). Ultrasound applications for the
666 extraction, identification and delivery of food proteins and bioactive peptides. *Trends in*
667 *Food Science & Technology*, 46(1), 60-67.

668 Kielty, C., & Grant, M. (2002). The collagen family: Structure, assembly, and organization in the
669 extracellular matrix. In P. Royce & B. Steinmann (Eds.), *Connective Tissue and Its Heritable*
670 *Disorders: Molecular, Genetic, and Medical Aspects* (Second ed., pp. 159-221). Hoboken, NJ,
671 USA: John Wiley & Sons, Inc

672 Korhonen, H., Pihlanto-Leppäla, A., Rantamäki, P., & Tupasela, T. (1998). Impact of processing on
673 bioactive proteins and peptides. *Trends in Food Science & Technology*, 9(8), 307-319.

674 Korhonen, H., & Pihlanto, A. (2006). Bioactive peptides: Production and functionality. *International*
675 *Dairy Journal*, 16(9), 945-960..

676 Kotch, F. W., & Raines, R. T. (2006). Self-assembly of synthetic collagen triple helices. *Proc Natl Acad*
677 *Sci U S A*, 103(9), 3028-3033.

678 Kumar, P., Satyam, A., Cigognini, D., Pandit, A., & Zeugolis, D. (In Press). Low oxygen tension and
679 macromolecular crowding accelerate extracellular matrix deposition in human corneal
680 fibroblast culture. *J Tissue Eng Regen Med*.

681 Lee, S.-J., Kim, E.-K., Hwang, J.-W., Oh, H.-J., Cheong, S.-H., Moon, S.-H., . . . Park, P.-J. (2010).
682 Purification and characterisation of an antioxidative peptide from enzymatic hydrolysates of
683 duck processing by-products. *Food Chemistry*, 123(2), 216-220.

684 Lemes, A. C., Sala, L., Ores, J. d. C., Braga, A. R. C., Egea, M. B., & Fernandes, K. F. (2016). A review of
685 the latest advances in encrypted bioactive peptides from protein-rich waste. *International*
686 *Journal of Molecular Sciences*, 17(6), 950.

687 Leoci, R. (2014). *Animal by-products (ABPs): origins, uses, and European regulations*: Universitas
688 Studiorum.

689 Li, H., Zhu, K., Zhou, H., & Peng, W. (2012). Effects of high hydrostatic pressure treatment on
690 allergenicity and structural properties of soybean protein isolate for infant formula. *Food*
691 *Chemistry*, 132(2), 808-814.

692 Linder, M., Fanni, J., Parmentier, M., Sergent, M., & Phan-Tan-Luu, R. (1995). Protein recovery from
693 veal bones by enzymatic hydrolysis. *Journal of Food Science*, 60(5), 949-952.

694 Looy, H., Dunkel, F. V. & Wood, J. R. (2014). How then shall we eat? Insect-eating attitudes and
695 sustainable foodways, *Agriculture and Human Values*, 31 (1), 131-141.

696 López, M. A., & Martos, F. C. (2004). Iron availability: An updated review. *International Journal of*
697 *Food Sciences and Nutrition*, 55(8), 597-606.

698 Lynch, S., Mullen, A. M., O'Neill, E., & Álvarez, C. (2017). Harnessing the potential of blood proteins
699 as functional ingredients. A review of the state of art in blood processing. *Comprehensive*
700 *Reviews in Food Science and Food Safety*.

701 Lynn, A. K., Yannas, I. V., & Bonfield, W. (2004). Antigenicity and immunogenicity of collagen. *J*
702 *Biomed Mater Res B*, 71B(2), 343-354.

703 Hickey, G. (2014) Bord Bia Food Alert: Sports Nutrition now more convenient than ever in Ireland.
704 Available on: <http://www.bordbia.ie/industry/manufacturers/insight/alerts/Pages/SportsNutritionnowmoreconvenientthaneverinireland.aspx?year=2014&wk=24>. Accessed on
705 February 2017.

706

707 King, H. (2011) Bord Bia Market report: Sports Nutrition - The European Market Publication Date:
708 23/06/2011. Available at:
709 [http://www.bordbia.ie/industry/manufacturers/insight/publications/bbreports/Documents/](http://www.bordbia.ie/industry/manufacturers/insight/publications/bbreports/Documents/Sports%20Nutrition%20-20The%20European%20Market.pdf)
710 [Sports%20Nutrition%20-20The%20European%20Market.pdf](http://www.bordbia.ie/industry/manufacturers/insight/publications/bbreports/Documents/Sports%20Nutrition%20-20The%20European%20Market.pdf). Accessed on February 2017

711 Marcet, I., Alvarez, C., Paredes, B., & Diaz, M. (2016). The use of sub-critical water hydrolysis for the
712 recovery of peptides and free amino acids from food processing wastes. Review of sources
713 and main parameters. *Waste Manag*, 49, 364-371.

714 Marti, D. L., Johnson, R. J., & Mathews Jr, K. H. (2012). Where's the (not) meat? Byproducts from
715 beef and pork production. *Journal of Current Issues in Globalization*, 5(4), 397.

716 Martins, Y., Pelchat M.L. & Pliner P. (1997). Try it; it's good and it's good for you": effects of taste and
717 nutrition information on willingness to try novel foods. *Appetite*. 28(2):89-102.

718 Millward, D. J., Layman, D. K., Tomé, D., & Schaafsma, G. (2008). Protein quality assessment: impact
719 of expanding understanding of protein and amino acid needs for optimal health. *The*
720 *American journal of clinical nutrition*, 87(5), 1576S-1581S.

721 Montero Castillo, P. M., Ligardo, M., Alejandro, Y., González, J., & Cristina, L. (2015). Protein Quality
722 of Rice Drinks Fortified with Bovine and Porcine Blood Plasma. *Revista Facultad Nacional de*
723 *Agronomía, Medellín*, 68(1), 7487-7496.

724 Mullen, A.M., & Álvarez, C. (2016). Offal: types and composition. *The Encyclopedia of Food and*
725 *Health*, 4, 152-157.

726 Mullen, A. M., Álvarez, C., Pojić, M., Hadnadev, T. D., & Papageorgiou, M. (2015). Classification and
727 target compounds. 25-57.

728 Murray, S. M., Patil, A. R., Fahey, G. C., Merchen, N. R., & Hughes, D. M. (1997). Raw and rendered
729 animal by-products as ingredients in dog diets. *Journal of animal science*, 75(9), 2497-2505.

730 Myllyharju, J., Lamberg, A., Notbohm, H., Fietzek, P. P., Pihlajaniemi, T., & Kivirikko, K. I. (1997).
731 Expression of wild-type and modified pro alpha chains of human type I procollagen in insect
732 cells leads to the formation of stable [alpha 1(I)](2)alpha 2(I) collagen heterotrimers and
733 [alpha 1(I)](3) homotrimers but not [alpha 2(I)](3) homotrimers. *J Biol Chem*, 272(35), 21824-
734 21830.

735 O'Leary, L. E., Fallas, J. A., Bakota, E. L., Kang, M. K., & Hartgerink, J. D. (2011). Multi-hierarchical self-
736 assembly of a collagen mimetic peptide from triple helix to nanofibre and hydrogel. *Nat*
737 *Chem*, 3(10), 821-828.

738 O'Leary, L. E., Fallas, J. A., & Hartgerink, J. D. (2011). Positive and negative design leads to
739 compositional control in AAB collagen heterotrimers. *J Am Chem Soc*, 133(14), 5432-5443.

740 O'Sullivan, S., Lafarga, T., Hayes, M., & O'Brien, N. (2016). Potential bioactivity of hydrolysates
741 derived from bovine lung. *Proceedings of the Nutrition Society*, 75(OCE3).

742 Ofori, J. A., & Hsieh, Y.-H. P. (2012). *The use of blood and derived products as food additives*: INTECH
743 Open Access Publisher.

744 Olsen, D. R., Leigh, S. D., Chang, R., McMullin, H., Ong, W., Tai, E., . . . Toman, P. D. (2001).
745 Production of human type I collagen in yeast reveals unexpected new insights into the
746 molecular assembly of collagen trimers. *J Biol Chem*, 276(26), 24038-24043.

747 Pares, D., Toldra, M., Sagner, E., & Carretero, C. (2014). Scale-up of the process to obtain functional
748 ingredients based in plasma protein concentrates from porcine blood. *Meat Sci*, 96(1), 304-
749 310.

750 Pimentel, D., & Pimentel, M. (2003). Sustainability of meat-based and plant-based diets and the
751 environment. *The American journal of clinical nutrition*, 78(3), 660S-663S.

752 Power, O., Fernández, A., Norris, R., Riera, F. A., & FitzGerald, R. J. (2014). Selective enrichment of
753 bioactive properties during ultrafiltration of a tryptic digest of β -lactoglobulin. *Journal of*
754 *Functional Foods*, 9, 38-47.

755 Rele, S., Song, Y., Apkarian, R. P., Qu, Z., Conticello, V. P., & Chaikof, E. L. (2007). D-periodic collagen-
756 mimetic microfibers. *J Am Chem Soc*, 129(47), 14780-14787.

757 Rivera, J. A. (1998) Petfood: physico-chemical characteristics and functional properties of meat by-
758 products and mechanically separated chicken (MSC) in a high-moisture model system. Iowa
759 State University, PhD Thesis. Retrospective Theses and Dissertations. Paper 11886.

760 Rutschmann, C., Baumann, S., Cabalzar, J., Luther, K. B., & Hennet, T. (2014). Recombinant
761 expression of hydroxylated human collagen in *Escherichia coli*. *Appl Microbiol Biotechnol*,
762 98(10), 4445-4455.

763 Rozin, P. & Fallon, A. E. (1987), A perspective on disgust, *Psychological Review*, 94, 23-41

764 Ryan, J. T., Ross, R. P., Bolton, D., Fitzgerald, G. F., & Stanton, C. (2011). Bioactive peptides from
765 muscle sources: meat and fish. *Nutrients*, 3(9), 765-791.

766 Sarmadi, B. H., & Ismail, A. (2010). Antioxidative peptides from food proteins: a review. *Peptides*,
767 31(10), 1949-1956.

768 Satyam, A., Kumar, P., Cigognini, D., Pandit, A., & Zeugolis, D. (2016). Low, but not too low, oxygen
769 tension and macromolecular crowding accelerate extracellular matrix deposition in human
770 dermal fibroblast culture. *Acta Biomater*, 44, 221-231.

771 Satyam, A., Kumar, P., Fan, X., Gorelov, A., Rochev, Y., Joshi, L., . . . Zeugolis, D. (2014).
772 Macromolecular crowding meets tissue engineering by self-assembly: A paradigm shift in
773 regenerative medicine. *Adv Mater*, 26(19), 3024-3034.

774 Selmane, D., Christophe, V., & Gholamreza, D. (2008). Extraction of proteins from slaughterhouse by-
775 products: Influence of operating conditions on functional properties. *Meat Sci*, 79(4), 640-
776 647.

777 Sharma, S., Singh, R., & Rana, S. (2011). Bioactive peptides: a review. *Int J Bioautomation*, 15(4), 223-
778 250.

779 Schmidt, C. (2014). The rise of protein in the global health and wellness and supplement arenas –
780 Examining the global protein surge. Presented at the Protein Trends & Technologies
781 Seminar, April 8-9, 2014, Arlington Heights, IL, USA. Available at
782 [https://www.globalfoodforums.com/wp-content/uploads/2014/04/Chris-Schmidt-](https://www.globalfoodforums.com/wp-content/uploads/2014/04/Chris-Schmidt-Euromonitor-2014-Protein-Trends-Technologies.pdf)
783 [Euromonitor-2014-Protein-Trends-Technologies.pdf](https://www.globalfoodforums.com/wp-content/uploads/2014/04/Chris-Schmidt-Euromonitor-2014-Protein-Trends-Technologies.pdf). Accessed on February 2017.

784 Smeller, L. (2002). Pressure–temperature phase diagrams of biomolecules. *Biochimica et Biophysica*
785 *Acta (BBA)-Protein Structure and Molecular Enzymology*, 1595(1), 11-29.

786 Soliva-Fortuny, R., Balasa, A., Knorr, D., & Martín-Belloso, O. (2009). Effects of pulsed electric fields
787 on bioactive compounds in foods: a review. *Trends in Food Science & Technology*, 20(11),
788 544-556.

789 Sorushanova, A., Delgado, L., Wu, Z., Shologu, N., Kshirsagar, A., Raghunath, R., . . . Zeugolis, D.
790 (Submitted). New tricks for the orld protein - The next generation of collagen-based devices.
791 *Prog Polym Sci*.

792 Steen, L., Glorieux, S., Goemaere, O., Brijs, K., Paelinck, H., Foubert, I., & Fraeye, I. (2016). Functional
793 properties of pork liver protein fractions. *Food and Bioprocess Technology*, 9(6), 970-980.

794 Stein, H., Wilensky, M., Tsafir, Y., Rosenthal, M., Amir, R., Avraham, T., . . . Shoseyov, O. (2009).
795 Production of bioactive, post-translationally modified, heterotrimeric, human recombinant
796 type-I collagen in transgenic tobacco. *Biomacromolecules*, 10(9), 2640-2645.

797 Sun, L. (2013). Peptide-based drug development. *Modern Chemistry & Applications*, 2013.

798 Thomas, D., Gaspar, D., Sorushanova, A., Milcovich, G., Spanoudes, K., Mullen, A.M., . . . Zeugolis, D.
799 (2016). Scaffold and scaffold-free self-assembled systems in regenerative medicine.
800 *Biotechnol Bioeng*, 113(6), 1155-1163.

801 Toldra, F., Aristoy, M. C., Mora, L., & Reig, M. (2012). Innovations in value-addition of edible meat
802 by-products. *Meat Sci*, 92(3), 290-296.

803 Toldrá, F., Mora, L., & Reig, M. (2016). New insights into meat by-product utilization. *Meat science*,
804 120, 54-59.

805 Toman, P. D., Pieper, F., Sakai, N., Karatzas, C., Platenburg, E., de Wit, I., . . . Platenburg, G. J. (1999).
806 Production of recombinant human type I procollagen homotrimer in the mammary gland of
807 transgenic mice. *Transgenic Res*, 8(6), 415-427.

808 Tomita, M., Munetsuna, H., Sato, T., Adachi, T., Hino, R., Hayashi, M., . . . Yoshizato, K. (2003).
809 Transgenic silkworms produce recombinant human type III procollagen in cocoons. *Nat*
810 *Biotechnol*, 21(1), 52-56

811 Trostle, R. (2008). *Global agricultural supply and demand: factors contributing to the recent increase*
812 *in food commodity prices*: US Department of Agriculture, Economic Research Service
813 Washington, DC.

814 USDA-FSIS Directive 7120.1. (2017) Safe and suitable ingredients used in the production of meat,
815 poultry, and egg products. Revision 39, 1/9/17

816 USDA-FSIS (1999). Saving of blood from livestock as an edible product. *Federal Register / Vol. 64, No.*
817 *246 Part 9 CFR 310.20*

818 Van, D. M. P. C. (2001). Food products processed from offal components: Google Patents.

819 Van Huis, A., Van Itterbeeck, J., Klunder, H., Mertens, E., Halloran, A., Muir, G., & Vantomme, P.
820 (2013). *Edible insects: future prospects for food and feed security*: Food and agriculture
821 organization of the United nations (FAO).

822 Venegas Fornias, O. (1996). Edible by-products of slaughter animals. *FAO Animal Production and*
823 *Health Paper (FAO)*.

824 Vernooij, A., (2012) The Return of Animal By-Products. Rabobank Industry Note #335 –Dec 2012.
825 Downloaded from [http://ausrenderers.com.au/index.php/downloads/category/1-general-](http://ausrenderers.com.au/index.php/downloads/category/1-general-documents)
826 [documents](http://ausrenderers.com.au/index.php/downloads/category/1-general-documents) 7th Feb 2017

827 Vuorela, A., Myllyharju, J., Nissi, R., Pihlajaniemi, T., & Kivirikko, K. I. (1997). Assembly of human
828 prolyl 4-hydroxylase and type III collagen in the yeast *pichia pastoris*: Formation of a stable
829 enzyme tetramer requires coexpression with collagen and assembly of a stable collagen
830 requires coexpression with prolyl 4-hydroxylase. *EMBO J*, 16(22), 6702-3712.

831 Waldron, K. (2007). *Waste minimization, management and co-product recovery in food processing:*
832 *an introduction* (Vol. 1): Woodhead Publishing Limited: Cambridge, UK.

833 Williams, P. (2007). Nutritional composition of red meat. *Nutrition & Dietetics*, 64(s4), S113-S119.

834 Wilson, Marc (2011). The probable value of the US dried animal blood plasma market is \$29 million
835 per annum. Global Advisors, online article published on 5 December 2011. Available at:
836 [http://www.globaladvisors.biz/fast-facts/20111205/the-probable-value-of-the-us-dried-](http://www.globaladvisors.biz/fast-facts/20111205/the-probable-value-of-the-us-dried-animal-blood-plasma-market-is-29-million-per-annum/)
837 [animal-blood-plasma-market-is-29-million-per-annum/](http://www.globaladvisors.biz/fast-facts/20111205/the-probable-value-of-the-us-dried-animal-blood-plasma-market-is-29-million-per-annum/). Accessed on February 2017

838 Zeugolis, D. I., Paul, R. G., & Attenburrow, G. (2008). Factors influencing the properties of
839 reconstituted collagen fibers prior to self-assembly: animal species and collagen extraction
840 method. *J Biomed Mater Res A*, 86(4), 892-904.

841 Zeugolis, D. I., Paul, G. R., & Attenburrow, G. (2009). Cross-linking of extruded collagen fibers—A
842 biomimetic three-dimensional scaffold for tissue engineering applications. *Journal of*
843 *Biomedical Materials Research Part A*, 89(4), 895-908.

844 Zhang, C., Baez, J., Pappu, K. M., & Glatz, C. E. (2009). Purification and characterization of a
845 transgenic corn grain-derived recombinant collagen type I alpha 1. *Biotechnol Prog*, 25(6),
846 1660-1668.

847 Zou, Y., Wang, L., Li, P., Cai, P., Zhang, M., Sun, Z., . . . Xu, X. (2017). Effects of ultrasound assisted
848 extraction on the physiochemical, structural and functional characteristics of duck liver
849 protein isolate. *Process Biochemistry*, 52, 174-182.
850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867 **Tables**

868 Table 1: Total protein content (% wet basis), individual essential amino acids (g/100 g protein) and
 869 total essential amino acids (%EAA) in selected offal across a number of species.

Product	Specie	Prot. (%)	Lys	Met	Trp	% EAA
Blood	Cattle	17-18	9.7	2.4	-	60.6
	Porcine	18.5	9.0	2.3	1.5	58
Brain	Cattle	10.5	6.0	2.1	4.7	42.8
	Porcine	10.3	7.8	2.0	4.2	46.8
	Sheep	12.3	6.4	2.0	1.1	42.8
Heart	Cattle	17	8.2	2.6	1.1	47.1
	Porcine	17	8.3	2.6	1.2	47.7
	Sheep	18	7.5	2.2	1.1	43.8
Kidney	Cattle	15.3	6.6	2.1	1.4	45.2
	Porcine	15.4	7.2	2.1	1.3	48.0
	Sheep	18.0	6.5	2.0	1.4	43.9
Liver	Cattle	21	6.9	2.5	1.4	49.1
	Porcine	19	7.7	2.5	1.4	48.9
	Sheep	20.3	5.4	2.1	1.2	42.7
Lung	Cattle	17	7.1	2.0	0.9	41.5
	Porcine	15	7.3	1.6	0.9	37.8
	Sheep	12.5	6.5	1.8	0.9	40.6
Spleen	Cattle	19	7.2	1.8	1.0	48.0
	Porcine	17.9	7.5	1.8	1.0	41.9
	Sheep	17.2	7.7	1.9	1.1	48.5
Tongue	Cattle	17.1	7.7	2.1	0.8	45.8
	Porcine	16.3	8.2	2.2	1.2	40.2
	Sheep	15.3	7.1	2.1	1.0	40.4
Connective tissue collagen		85%	3.5	0.7	0.0	11.97

870 Data from Venegas, 1996.

871

872

873

874

875

876

877

Compound	Concentration (mg/g)	Biological function
Conjugated linoleic acid	3-8 (beef fat)	Reduced risk of colorectal cancer and diabetes, antioxidant, immunomodulatory.
Carnosine	2.7 (pork shoulder)	Antioxidant
Anserine	nd	Antioxidant, metal chelating
L-carnitine	1.3 (beef thigh)	Lowering-cholesterol, calcium absorption, prevention of muscle myopathy
Glutathione	0.12-0.26 (beef muscle)	Antioxidant, defence against toxicological and pathological processes
Taurine	0.77 (beef muscle)	Eye health, preventing heart disease, essential in some stages (lactation or immune challenge)
Coenzyme Q10	0.02 (beef muscle)	Antioxidant
Creatine	3.5 (beef muscle)	Enhancing muscle performance

879 *Adapted from (Arihara and Ohata (2008))

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894 Table 3: Main Regulations and Directives regarding the use of meat processing co-products
 895 in Europe

Scope	Reference	Short description
General	Reg.(EC) 999/2001	rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies in animals
	Directive 2008/98/EC	concepts and definitions related to waste management, such as definitions of waste, recycling, recovery
	Directive 2008/1/EC	integrated pollution prevention and control
	Reg.(EC) 1069/2009	health rules as regards animal by-products and derived products not intended for human consumption
For human consumption	“Hygiene Package”	
	· Reg.(EC) 852/2004	on the hygiene of foodstuffs;
	· Reg.(EC) 853/2004	specific hygiene rules for food of animal origin;
	· Reg.(EC) 854/2004	specific rules for products of animal origin intended for human consumption
	Reg.(EC) 1169/2011	provision of food information to consumers
	Reg.(EC) 609/2013	food intended for infants and young children, food for special medical purposes, and total diet replacement for weight control
	Reg.(EC) 1333/2008	approved food additives and their conditions of use
Specific applications	Reg.(EC) 1332/2008	enzymes used in food
	Directive 76/768/EEC	cosmetic products
	Directive 90/385/EEC	medical implants
	Directive 2003/32/EC	medical devices
	Directive 89/79/EC	<i>In vitro</i> diagnostic medical devices
	Directive 2001/82/EC	vet medical products
	Directive 2001/83/EC	medicinal products

896
 897
 898
 899
 900
 901
 902
 903
 904
 905

906 Table 4: Examples of revalorising techniques for adding value to several meat co-products.

Product	Revalorizing techniques	High added-value products
Liver	Enzymatic hydrolysis	Antioxidant peptides
Heart	Isoelectric solubilization/precipitation	High value protein with low ash, fat and cholesterol
	Phosphate buffer washing	Myofibrillar concentrate as texturizing
Skin	Collagen recovery	Barrier membrane, drug delivery, fibroblast scaffolds, bioengineered tissues
	Enzymatic hydrolysis and chromatographic purification	Antioxidant peptides and liver protectors
	Collagen hydrolysis	Antioxidant activity, antimicrobial properties antihypertensive, biomimetic tissue
Blood	Enzymatic hydrolysis	Antioxidant, antibacterial, antihypertensive or iron-binding peptides
	Chemical hydrolysis	Pre-digested peptides for animal and pet food
	Ethanol precipitation	Purified protein as food ingredient
	High pressure treatment	Peptides and biopreserved blood
		Amino acid and peptides production
Bone	Subcritical water hydrolysis	
	Subcritical water	Hydroxyapatite and collagen
	Alkaline extraction	New kind of sausages
Lung	Isoelectric solubilization - precipitation and membrane filtration	Protein concentrates with good functional properties
Feathers and hair	Keratinolytic bacteria fermentation and enzymatic hydrolysis	Keratinolytic protease production, culture medium, soil assessment, separation membranes

907 *Adapted from Mullen, Álvarez, Pojić, Hadnadev, & Papageorgiou, 2015.